Core Viewpoint - Zhonghui Biotech-B (02627) is set to launch an initial public offering (IPO) from July 31 to August 5, 2025, aiming to issue 33.44 million H-shares globally, with 10% allocated for Hong Kong and 90% for international investors, at a price range of HKD 12.9 to HKD 15.5 per share [1] Group 1 - The company is a China-based vaccine manufacturer focused on the research, development, and commercialization of innovative vaccines and traditional vaccines using new technologies [1] - The product pipeline includes two core products: a quadrivalent influenza virus subunit vaccine and an investigational freeze-dried human rabies vaccine, along with 11 other vaccines in development [1] Group 2 - The cornerstone investors, including Jiaxing Xinyang and Huatai Capital Investment, have agreed to subscribe for shares worth USD 13 million, with an estimated total of 7.1136 million H-shares to be purchased at a midpoint price of HKD 14.20 per share [2] - This subscription represents approximately 21.3% of the total shares offered in the global sale, assuming no exercise of the over-allotment option [2] Group 3 - The net proceeds from the global offering are estimated to be around HKD 421 million after deducting underwriting fees and expenses, with approximately 63.6% allocated to the development and registration of core products [3] - Specific allocations include about 32.4% for the continued R&D and overseas registration of the quadrivalent influenza virus subunit vaccine, and about 31.2% for the Phase III clinical trials and registration of the investigational freeze-dried human rabies vaccine [3] - Additional funds will be used for the development of other investigational vaccines, enhancement of production and commercialization capabilities, and the development of various technological platforms [3]
中慧生物-B(02627)于7月31日至8月5日招股 拟全球发售3344.26万股H股
智通财经网·2025-07-30 23:45